Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $4.75 and traded as high as $5.15. Adial Pharmaceuticals shares last traded at $5.05, with a volume of 83,319 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on ADIL shares. Weiss Ratings upgraded Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Alliance Global Partners began coverage on shares of Adial Pharmaceuticals in a research report on Monday, August 3rd. They set a “buy” rating and a $11.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.33.
Get Our Latest Analysis on Adial Pharmaceuticals
Adial Pharmaceuticals Stock Performance
The stock has a market capitalization of $12.80 million, a P/E ratio of -0.33 and a beta of 1.50. The company’s fifty day simple moving average is $4.71 and its two-hundred day simple moving average is $3.27.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapeutics for addiction and related disorders. The company’s primary product candidate is AD04, an investigational formulation of ondansetron, a serotonin 5-HT3 receptor antagonist, being developed as a pharmacogenetically targeted treatment for alcohol use disorder.
AD04 is designed for people with alcohol use disorder who have specific genetic characteristics that may influence treatment response.
Featured Articles
- Five stocks we like better than Adial Pharmaceuticals
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
